Assessment of ceftaroline fosamil in the treatment of community-acquired bacterial pneumonia due to Streptococcus pneumoniae: Insights from two randomized trials

Diagnostic Microbiology and Infectious Disease

Volumn 75, Issue 3, 2013, Pages 298-303

  Shorr, Andrew F ^a   Kollef, Marin ^b   Eckburg, Paul B ^c   Llorens, Lily ^d,e   Friedland, H David ^d,e  

^a WASHINGTON HOSPITAL CENTER   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d FOREST RESEARCH INSTITUTE   (United States)

^e NONE

Author keywords

Ceftaroline fosamil; Ceftriaxone; Community acquired bacterial pneumonia; Streptococcus pneumoniae

Indexed keywords

CEFTAROLINE FOSAMIL; CEFTRIAXONE;

AGED; ARTICLE; BACTERIAL PNEUMONIA; COHORT ANALYSIS; COMMUNITY ACQUIRED BACTERIAL PNEUMONIA; COMMUNITY ACQUIRED PNEUMONIA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; STREPTOCOCCUS PNEUMONIAE; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BACTEREMIA; CEFTRIAXONE; CEPHALOSPORINS; COMMUNITY-ACQUIRED INFECTIONS; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; ODDS RATIO; PNEUMONIA, PNEUMOCOCCAL; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84873721190     PISSN: 07328893     EISSN: 18790070     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2012.12.002     Document Type: Article

References (26)

1. Adamuz J., Viasus D., Campreciós-Rodríguez P., Cañavate-Jurado O., Jiménez-Martínez E., Isla P., et al. A prospective cohort study of healthcare visits and rehospitalizations after discharge of patients with community-acquired pneumonia. Respirology 2011, 16(7):1119-1126.
2. Cornick J.E., Bentley S.D. Streptococcus pneumoniae: the evolution of antimicrobial resistance to beta-lactams, fluoroquinolones and macrolides. Microbes Infect 2012, 14(7-8):573-583.
3. Croisier-Bertin D., Piroth L., Charles P.-E., Larribeau A., Biek D., Ge Y., et al. Ceftaroline versus ceftriaxone in a highly penicillin-resistant pneumococcal pneumonia rabbit model using simulated human dosing. Antimicrob Agents Chemother 2011, 55(7):3557-3563.
4. File T.M., Marrie T.J. Burden of community-acquired pneumonia in North American adults. Postgrad Med 2010, 122(2):130-141.
5. File T.M., Low D.E., Eckburg P.B., Talbot G.H., Friedland H.D., Lee J., et al. FOCUS 1: A randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia. J Antimicrob Chemother 2011, 66(Suppl 3):iii19-iii32.
6. File T.M., Low D.E., Eckburg P.B., Talbot G.H., Friedland H.D., Lee J., et al. Integrated analysis of FOCUS 1 and FOCUS 2: randomized, double-blinded, multicenter phase 3 trials of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in patients with community-acquired pneumonia. Clin Infect Dis 2010, 51:1395-1405.
7. Ge Y., Biek D., Talbot G.H., Sahm D.F. In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States. Antimicrob Agents Chemother 2008, 9(52):3398-3407.
8. Gertz R.E., Li Z., Pimenta F.C., Jackson D., Juni B.A., Lynfield R., et al. Increased penicillin nonsusceptibility of nonvaccine-serotype invasive pneumococci other than serotypes 19A and 6A in post-7-valent conjugate vaccine era. J Infect Dis 2010, 201:770-775.
9. Hall M.J., DeFrances C.J., Williams S.N., Golosinskiy A., Schwartzman A. National Hospital Discharge Survey: 2007 Summary. National Health Statistics Reports; no 29 2010, National Center for Health Statistics, Hyattsville, MD.
10. Iizawa Y., Nagai J., Ishikawa T., Hashiguchi S., Nakao M., Miyake A., et al. In vitro antimicrobial activity of T-91825, a novel anti-MRSA cephalosporin, and in vivo anti-MRSA activity of its prodrug, TAK-599. J Infect Chemother 2004, 10(3):146-156.
11. Jencks S.F., Williams M.V., Coleman E.A. Rehospitalizations among patients in the Medicare Fee-for-Service program. N Engl J Med 2009, 360:1418-1428.
12. Jones R.N., Sader H.S., Moet G.J., Farrell D.J. Declining antimicrobial susceptibility of Streptococcus pneumoniae in the United States: report from the SENTRY Antimicrobial Surveillance Program (1998-2009) [letter]. Diagn Microbiol Infect Dis 2010, 68:334-336.
13. Kosowska-Shick K., McGhee P.L., Appelbaum P.C. Affinity of ceftaroline and other β-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae. Antimicrob Agents Chemother 2010, 54(5):1670-1677.
14. Low D.E., File T.M., Eckburg P.B., Talbot G.H., Friedland H.D., Lee J., et al. FOCUS 2: A randomized, double-blinded, multicentre, phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia. J Antimicrob Chemother 2011, 66(Suppl 3):iii33-iii44.
15. Mandell L.A., Wunderink R.G., Anzueto A., Bartlett J.G., Campbell G.D., Dean N.C., et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007, 44(Suppl 2):S27-S72.
16. Moisan H., Pruneau M., Malouin F. Binding of ceftaroline to penicillin-binding proteins of Staphylococcus aureus and Streptococcus pneumoniae. J Antimicrob Chemother 2010, 65:713-716.
17. Moore M.R., Gertz R.E., Woodbury R.L., Barkocy-Gallagher G., Schaffner W., Lexau C., et al. Population snapshot of emergent Streptococcus pneumoniae serotype 19A in the United States, 2005. J Infect Dis 2008, 197:1016-1027.
18. Niederman M.S. Community-acquired pneumonia: the U.S. perspective. Semin Respir Crit Care Med 2009, 30:179-188.
19. Niederman M.S., Mandell L.A., Anzueto A., Bass J.B., Broughton W.A., Campbell G.D., et al. Guidelines for the management of adults with community-acquired pneumonia: diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med 2001, 163:1730-1754.
20. Rank D.R., Friedland H.D., Laudano J.B. Integrated safety summary of FOCUS 1 and FOCUS 2 trials: phase III randomized, double-blind studies evaluating ceftaroline fosamil for the treatment of patients with community-acquired pneumonia. J Antimicrob Chemother 2011, 66(Suppl 3):iii53-iii59.
21. Richter S.S., Heilmann K.P., Dohrn C.L., Riahi F., Beekmann S.E., Doern G.V. Changing epidemiology of antimicrobial-resistant Streptococcus pneumoniae in the United States, 2004-2005. Clin Infect Dis 2009, 48:e23-e33.
22. Sader H.S., Fritsche T.R., Kaniga K., Ge Y., Jones R.N. Antimicrobial activity and spectrum of PPI-0903M (T-91825), a novel cephalosporin, tested against a worldwide collection of clinical strains. Antimicrob Agents Chemother 2005, 49(8):3501-3512.
23. Steed M.E., Vidaillac C., Winterfield P., Biek D., Rybak M.J. Evaluation of ceftaroline activity versus ceftriaxone against clinical isolates of Streptococcus pneumoniae with various susceptibilities to cephalosporins in an in vitro pharmacokinetic/pharmacodynamic model. Antimicrob Agents Chemother 2012, 56(5):2691-2695.
24. Tauber S.C., Nau R. Immunomodulatory properties of antibiotics. Curr Mol Pharmacol 2008, 1:68-79.
25. Welte T., Torres A., Nathwani D. Clinical and economic burden of community-acquired pneumonia among adults in Europe. Thorax 2012, 67:71-79.
26. Xu J.Q., Kochanek K.D., Murphy S.L., Tejada-Vera B. Deaths: final data for 2007. National Vital Statistics Report. Vol 58 no 19 2010, National Center for Health Statistics, Hyattsville, MD, http://www.cdc.gov/nchs/data/nvsr/nvsr58/nvsr58_19.pdf. Accessed July 27, 2011.